首页 > 市场调查报告书 > 製药

神经疾病

市场调查报告书

商品编码

1378670

帕金森氏症药物市场：按药物类别、给药途径、配销通路和地区

Parkinsons Disease Therapeutics Market, By Drug Class (Levodopa, Dopamine agonists, MAO-B inhibitors, Anticholinergics, Others ), By Route of Administration (Oral, Injectable, Nasal, Transdermal, Others ), By Distribution Channel, By Geography

出版日期: 2023年10月10日 | 出版商:

Coherent Market Insights | 英文 312 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计到 2023 年，全球帕金森氏症治疗市场将达到 51.1 亿美元，预计在预测期内（2023-2030 年）年复合成长率为 7.0%。

报告范围		报告详情
基准年	2022年	2023年市场规模	51.1亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期年复合成长率	7.00%	2030年市场规模预测	82亿美元

图 1. 2023 年帕金森氏症药物的全球市场占有率(%)（依药物类别）

帕金森氏症是一种由神经系统疾病引起的运动障碍。震颤、运动缓慢、肌肉僵硬、步态不稳定以及平衡和协调问题都是帕金森氏症的常见症状。左旋多巴、多巴胺促效剂、MAO-B 抑制剂和抗胆碱能药物是一些用于治疗帕金森氏症的药物。左旋多巴（也称为左旋多巴）是治疗帕金森氏症最常用的处方药。左旋多巴可有效控制诸如运动缓慢和身体某些部位僵硬或僵硬等症状。大多数患者可以透过药物治疗维持高品质的生活，对于某些患者来说，症状可以透过手术来改善。另一种称为去甲肾上腺素的神经传导物质在帕金森氏症患者中也会减少。该分子是交感神经系统正常运作所必需的。身体的一些自主神经活动，如消化、心率、血压和呼吸，都是由这个系统控制的。帕金森氏症的一些非运动症状是由于去甲肾上腺素缺乏所引起的。运动可以显着改善帕金森氏症的症状。物理、职业和语言治疗还可以改善步态和平衡问题、饮食和吞嚥障碍以及语言障碍。

市场动态

市场参与者正专注于推出新产品，预计这将在预测期内推动帕金森氏症药物市场的成长。例如，2020年5月，美国公司Sunovion Pharmaceuticals Inc.推出了KYNMOBI（阿朴吗啡吗啡）舌下膜，作为帕金森氏症患者OFF发作（即PD症状復发或恶化）的急性间歇治疗。食品药物管理局核准。 KYNMOBI 有不同的规格：10 毫克、15 毫克、20 毫克和 25 毫克。

本研究的主要特点

本报告对全球帕金森氏症药物市场进行了详细分析，并呈现了以2022年为基准年的预测期（2023-2030年）的市场规模和复合年度（年复合成长率）。
它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
它根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数，介绍了全球帕金森氏症治疗药物市场的主要企业。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
全球帕金森氏症治疗药物市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球帕金森氏症治疗药物市场的各种策略矩阵，将有助于相关人员做出决策。

公司简介
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- GlaxoSmithKline Plc.
- AbbVie Inc.
- Merck &Co., Inc.
- Zydus Cadila
- Dr. Reddy's Laboratories
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Boehringer Ingelheim International GmbH
- Denali Therapeutics Inc.
- Biogen Inc.
- Prevail Therapeutics
- Eli Lilly and Company
- Voyager Therapeutics

第10章章

参考
调查方法

简介目录

Product Code: CMI494

The global Parkinsons disease therapeutics market is estimated to be valued at US$ 5.11 Billion in 2023 and is expected to exhibit a CAGR of 7.0% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 5.11 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	7.00%	2030 Value Projection:	US$ 8.2 Bn

Figure 1. Global Parkinsons Disease Therapeutics Market Share (%), By Drug Class, 2023

Parkinsons Disease Therapeutics Market - IMG1

Parkinsons disease is a movement disorder caused by a neurological condition. Tremor, slowness of movement, tight muscles, an unsteady walk, balance, and coordination issues are all common symptoms of Parkinson disease. Levodopa, dopamine agonists, MAO-B inhibitors, and anticholinergics are some of the medications used for the treatment of Parkinson's disease. Levodopa (also called L-dopa) is the most commonly prescribed drug for Parkinson's disease. It is useful in controlling symptoms such as slow movements and stiff and rigid body parts. Medication allows the majority of patients to retain a high quality of life, and surgery can help some people improve their symptoms. Parkinson's disease patients also observe a decrease in another neurotransmitter known as norepinephrine. This molecule is required for the sympathetic nervous system to operate properly. Some of the body's autonomic activities are controlled by this system, including digestion, heart rate, blood pressure, and breathing. Some of the non-movement-related symptoms of Parkinson's disease are caused by a lack of norepinephrine. Exercise can considerably improve Parkinson's symptoms. Physical therapy, occupational therapy, and speech-language therapy can also assist with walking and balance issues, eating and swallowing difficulties, and speech disorders.

Market Dynamics

Market players are focusing on new product launches, which is expected to propel the Parkinsons disease therapeutic market growth during the forecast period. For instance, in May 2020, Sunovion Pharmaceuticals Inc., a pharmaceutical company, announced that it received U.S. Food and Drug Administration (FDA) approval for KYNMOBI (apomorphine hydrochloride) sublingual film for the acute, intermittent treatment for OFF episodes (i.e., re-emergence or worsening of PD symptoms) in patients with Parkinson's disease. KYNMOBI is available in different strengths, such as 10mg, 15mg, 20mg, and 25mg.

Key features of the study:

This report provides an in-depth analysis of the global Parkinsons disease therapeutic market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global Parkinsons disease therapeutic market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd., Cipla Inc., Boehringer Ingelheim International GmbH, Denali Therapeutics Inc., Biogen Inc., Prevail Therapeutics, Eli Lilly and Company and Voyager Therapeutics
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global Parkinsons disease therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Parkinsons disease therapeutic market.

Detailed Segmentation:

By Drug Class:
- Levodopa
- Dopamine agonists
- MAO-B inhibitors
- Anticholinergics
- Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine, among Others)
By Route of Admnistration:
- Oral
- Injectable
- Nasal
- Transdermal
- Others (Rectal, Sublingual, among Others)
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Company Profiles
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- GlaxoSmithKline Plc.
- AbbVie Inc.
- Merck & Co., Inc.
- Zydus Cadila
- Dr. Reddy's Laboratories
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Boehringer Ingelheim International GmbH
- Denali Therapeutics Inc.
- Biogen Inc.
- Prevail Therapeutics
- Eli Lilly and Company
- Voyager Therapeutics.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics

Drivers
Restraints
Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis

4. Global Parkinsons Disease Therapeutics Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Parkinsons Disease Therapeutics Market, By Drug Class, 2018- 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Levodopa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Dopamine agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
MAO-B inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Anticholinergics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine, among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

6. Global Parkinsons Disease Therapeutics Market, By Route of Administration, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Others (Rectal, Sublingual, among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

7. Global Parkinsons Disease Therapeutics Market, By Distribution Channel, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Parkinsons Disease Therapeutics Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
- `Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018 -2030, (US$ Bn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profiles
- Teva Pharmaceutical Industries Ltd.*
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Novartis AG
- GlaxoSmithKline Plc.
- AbbVie Inc.
- Merck & Co., Inc.
- Zydus Cadila
- Dr. Reddy's Laboratories
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Boehringer Ingelheim International GmbH
- Denali Therapeutics Inc.
- Biogen Inc.
- Prevail Therapeutics
- Eli Lilly and Company
- Voyager Therapeutics